Home > Financial Ratios > MANKIND PHARMA

MANKIND PHARMA
EV/Core EBITDA

    Back to All Ratios
MANKIND PHARMA is part of below Screeners ↓
Top Large Cap Stocks with Best Fundamentals
Best 1M Momentum Large Cap Stocks
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results

MANKIND PHARMA Last 5 Year EV/Core EBITDA History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   EV/Core EBITDA(x) 32.31-0.120.23-0.23-0.16

What is the latest EV/Core EBITDA ratio of MANKIND PHARMA ?

The latest EV/Core EBITDA ratio of MANKIND PHARMA is 32.31 based on Mar2024 Consolidated results.
Year EV/Core EBITDA
Mar202432.31
Mar2023-0.12
Mar20220.23
Mar2021-0.23
Mar2020-0.16

How is EV/Core EBITDA of MANKIND PHARMA Trending?

Years EV/Core EBITDA % Change
Mar2024 32.31
Positive
Mar2023 -0.12
Negative
Mar2022 0.23
Positive
Mar2021 -0.23
Negative
Mar2020 -0.16 -

Other Financial Ratios of MANKIND PHARMA


Compare EV/Core EBITDA ratio of peers of MANKIND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
MANKIND PHARMA ₹105,281.1 Cr 0.8% 15.9% 9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹428,725.0 Cr 3.1% 3.1% 17.5% Stock Analytics
DIVIS LABORATORIES ₹159,525.0 Cr 10.2% 6.7% 61.3% Stock Analytics
CIPLA ₹123,206.0 Cr 2.4% 2.5% 14% Stock Analytics
TORRENT PHARMACEUTICALS ₹109,519.0 Cr 2.1% 2.9% 31.4% Stock Analytics
DR REDDYS LABORATORIES ₹97,927.5 Cr 3.2% 1.3% -0.2% Stock Analytics


MANKIND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
MANKIND PHARMA

0.8%

15.9%

9%

SENSEX

0.8%

3.8%

8.4%


You may also like the below Video Courses